|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Assaf-Harofeh Medical Center |
|---|---|
| Information provided by: | Assaf-Harofeh Medical Center |
| ClinicalTrials.gov Identifier: | NCT00473733 |
Purpose
Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth.
We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients.
Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying.
Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus Type 2 |
Procedure: GLP receptors expression Procedure: ESOPHAGOGASTRODUODENOSCOPY |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Non-Randomized, Open Label, Active Control, Crossover Assignment |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Efrat Broide, MD | 972-8-9779722 | efibroide@yahoo.com |
| Israel | |
| Assaf Harofeh Medical Center | |
| Zerifin, Israel, 70300 | |
| Principal Investigator: | Efrat Broide, MD | Ethic committee of Asaaf Harofeh Medical Center |
More Information
| Study ID Numbers: | 65/07 |
| Study First Received: | May 13, 2007 |
| Last Updated: | May 14, 2007 |
| ClinicalTrials.gov Identifier: | NCT00473733 History of Changes |
| Health Authority: | Israel: "Ethic committee of Assaf Harofeh Medical Center" |
|
PATIENTS WITH DIABETES MELLITUS TYPE 2 UNDERGO UPPER ENDOSCOPY BIOPSIES FOR GLP RECEPTORS EXPRESSION PCR ANALYSIS |
|
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders |